RUBY-FILL (Rubidium Rb 82 Generator)
Generator-produced diagnostic radiopharmaceutical for cardiac PET myocardial perfusion imaging
Quick Facts About RUBY-FILL
Key Takeaways About RUBY-FILL
- Cardiac PET imaging tracer: RUBY-FILL is a closed-system generator that produces rubidium-82 chloride, a positron-emitting radiopharmaceutical used for PET myocardial perfusion imaging
- Diagnostic, not therapeutic: It is used to visualise blood flow to the heart muscle – it is not a treatment for any disease
- Very short half-life: Rubidium-82 has a physical half-life of approximately 75 seconds, so total radiation exposure per scan is low compared with many other cardiac imaging tests
- Institutional use only: RUBY-FILL is supplied only to licensed nuclear medicine facilities and is administered by trained personnel under the supervision of a physician qualified in the use of radioactive materials
- Often combined with a stress agent: Most rubidium-82 cardiac PET studies use a pharmacologic stress agent (regadenoson, adenosine, or dipyridamole) rather than exercise, and many reported symptoms during the scan are caused by that stress agent rather than by the tracer itself
What Is RUBY-FILL and What Is It Used For?
RUBY-FILL is a Rubidium Rb 82 chloride generator used to produce a short-lived radioactive diagnostic agent for positron emission tomography (PET) myocardial perfusion imaging. It is indicated for the evaluation of regional blood flow to the heart muscle in adult patients with known or suspected coronary artery disease.
RUBY-FILL belongs to the class of diagnostic radiopharmaceuticals – radioactive agents designed not to treat disease, but to produce medical images that help doctors diagnose or rule out a condition. In the case of RUBY-FILL, those images show how well blood flows through the muscle of the heart (the myocardium) at rest and when the heart is working harder than normal. This information helps cardiologists identify areas of the heart that are not receiving enough blood because of narrowed or blocked coronary arteries.
Technically, RUBY-FILL is not a vial of ready-to-inject medicine. It is a strontium-82 / rubidium-82 generator: a shielded device that continuously produces rubidium-82 from decaying strontium-82 through a process called radionuclide generation. The generator is connected to an automated infusion system that elutes (rinses out) the rubidium-82 chloride in sterile saline and delivers it directly to the patient through an intravenous line. Patients never see or handle the generator itself – only the injection that the infusion system delivers.
Rubidium-82 is used as a tracer for cardiac imaging because it behaves similarly to potassium in the body. Heart muscle cells take up rubidium-82 in proportion to regional blood flow, so areas of the myocardium that have healthy blood supply accumulate more tracer than areas supplied by narrowed coronary arteries. A PET scanner detects the pairs of gamma photons produced when the rubidium-82 decays, and a computer reconstructs cross-sectional images of the heart. Comparing images acquired at rest and during pharmacologic stress allows cardiologists to distinguish between normal myocardium, ischaemic (under-perfused but viable) tissue, and scar tissue from a previous heart attack.
Clinical studies and international guidelines, including those from the American Society of Nuclear Cardiology (ASNC), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the European Association of Nuclear Medicine (EANM), support the use of rubidium-82 PET for the evaluation of patients with known or suspected coronary artery disease. Cardiac PET is particularly useful in patients where other imaging tests (such as SPECT myocardial perfusion imaging) may be limited by body habitus, attenuation artefacts, or suboptimal image quality.
RUBY-FILL is used only as a diagnostic imaging agent. It is not prescribed to treat heart disease, chest pain, or any other condition. Your cardiac PET scan results will be interpreted by a physician and used, together with your symptoms and other test results, to guide decisions about further investigations or treatment.
What Should You Know Before Receiving RUBY-FILL?
Before a cardiac PET scan with RUBY-FILL, tell the nuclear medicine staff about all medical conditions, allergies, and medications, and especially about possible pregnancy or breastfeeding. Your medical team will screen for contraindications, particularly those related to the pharmacologic stress agent that is usually given alongside the tracer.
Safety screening before a rubidium-82 PET study focuses on two different sets of considerations: those related to the radiopharmaceutical itself (which are limited because rubidium-82 has a very short half-life and is administered in extremely small chemical amounts) and those related to the pharmacologic stress agent (regadenoson, adenosine, or dipyridamole) that is typically infused during the stress portion of the scan. Most contraindications in practice relate to the stress agent rather than to rubidium-82.
Contraindications
RUBY-FILL itself has no absolute contraindications listed in its prescribing information, other than known hypersensitivity to the product or its components. Allergic reactions to rubidium-82 chloride are extremely rare because the chemical amount injected is minute compared with typical doses of other injected drugs. However, your nuclear medicine team will still ask about previous adverse reactions to contrast media or radiopharmaceuticals.
More important contraindications usually relate to the pharmacologic stress protocol, not to RUBY-FILL itself. For example, regadenoson, adenosine, and dipyridamole are generally contraindicated in patients with: second- or third-degree atrioventricular (AV) block without a functioning pacemaker; sick sinus syndrome without a functioning pacemaker; severe symptomatic bradycardia; active bronchospasm or severe asthma; and recent ingestion of methylxanthines (caffeine, theophylline) which can interfere with vasodilator stress. Your healthcare team will screen you for these contraindications before deciding whether to proceed with stress PET imaging.
Patients with unstable cardiac conditions – such as acute coronary syndrome within the last 48 hours, decompensated heart failure, uncontrolled severe hypertension, or high-risk unstable arrhythmias – are generally not considered appropriate candidates for elective pharmacologic stress testing with rubidium-82 PET. The scan is usually postponed until the patient is stabilised.
Warnings and Precautions
Talk to your doctor or the nuclear medicine staff before your RUBY-FILL PET scan if any of the following apply to you:
- Asthma or chronic obstructive pulmonary disease (COPD): Vasodilator stress agents can precipitate bronchospasm. An alternative protocol (for example, dobutamine stress or no stress component) may be considered
- Heart rhythm problems: Inform the team if you have had AV block, sick sinus syndrome, long QT syndrome, or if you have a pacemaker or implantable defibrillator
- Seizure disorder: Aminophylline, which is sometimes used to reverse side effects of vasodilator stress, can lower the seizure threshold
- Severe kidney or liver impairment: Although rubidium-82 itself is rapidly cleared, other medications given around the scan may need dose adjustment
- Recent caffeine or theophylline use: Caffeine (coffee, tea, chocolate, cola, many soft drinks) can block the effect of adenosine and regadenoson. Most centres ask patients to avoid caffeine for at least 12–24 hours before a vasodilator stress test
- Claustrophobia: PET/CT scanners have relatively open gantries, but some patients still experience anxiety during imaging
- Radiation history: The nuclear medicine physician will consider your cumulative radiation exposure from other imaging tests, especially in younger patients
Radiation safety is a key element of every diagnostic radiopharmaceutical procedure. Nuclear medicine facilities work according to the ALARA principle (As Low As Reasonably Achievable), using the smallest activity of radiotracer necessary to produce a diagnostic image of acceptable quality. Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the International Atomic Energy Agency (IAEA), and EANM publish effective dose estimates for rubidium-82 studies; typical effective doses per rest/stress PET study are in the range of 3–5 millisieverts (mSv), comparable to a few months of natural background radiation exposure.
Pregnancy and Breastfeeding
RUBY-FILL is generally not recommended during pregnancy unless the diagnostic benefit to the mother clearly outweighs the potential radiation risk to the fetus. All women of childbearing potential should be asked about the possibility of pregnancy before the scan, and in many centres a pregnancy test is offered or required. If a cardiac PET is clinically necessary during pregnancy, the nuclear medicine physician and the referring cardiologist will discuss the benefit-risk balance with the patient and may consider alternative imaging strategies.
Because rubidium-82 has a physical half-life of only approximately 75 seconds, the radionuclide itself essentially decays to negligible levels within minutes of injection. For breastfeeding mothers, this short half-life means that a prolonged interruption of breastfeeding is usually not required for rubidium-82 alone. However, local protocols vary and may depend on the exact stress agent used, whether CT attenuation correction is performed, and institutional radiation-safety standards. Always follow the specific guidance provided by your nuclear medicine department.
For patients who may become pregnant, the nuclear medicine physician may perform the PET scan preferentially within the first 10 days after the start of menstruation (the “10-day rule”), when the probability of early pregnancy is lowest, unless the clinical situation requires more urgent imaging.
Tell your healthcare team before the scan if you are, or might be, pregnant, or if you are breastfeeding. Do not assume that a cardiac PET scan is automatically safe in these situations. Decisions must be individualised by a qualified nuclear medicine physician.
How Does RUBY-FILL Interact with Other Drugs?
Rubidium-82 itself has very few pharmacologic interactions because the chemical mass administered is tiny and the half-life is extremely short. Most clinically important interactions in rubidium-82 PET imaging concern medications that can affect the pharmacologic stress response or the interpretation of the scan – particularly caffeine, methylxanthines, beta-blockers, and nitrates.
Unlike conventional oral or injectable drugs, diagnostic radiopharmaceuticals such as rubidium-82 chloride do not typically undergo metabolic drug-drug interactions (for example, via cytochrome P450 enzymes). This is because they are given in extremely small chemical quantities and are rapidly cleared from the body through physical decay. Nevertheless, several classes of medication can still affect a rubidium-82 PET study, primarily by altering the cardiac stress response or the physiological uptake of the tracer.
Methylxanthines – including caffeine and theophylline – are competitive antagonists at adenosine receptors and can block the vasodilatory effect of adenosine, regadenoson, and dipyridamole, which are the most commonly used pharmacologic stress agents in rubidium-82 PET. Consumption of coffee, tea, cola, chocolate, or theophylline-containing medications in the hours before the scan can lead to false-negative or non-diagnostic results. For this reason, patients are typically asked to avoid all caffeine for 12–24 hours before a vasodilator stress PET.
Antianginal medications such as nitrates, beta-blockers, and calcium channel blockers do not make the scan unsafe, but they may alter the severity of reversible ischaemia seen on images. Depending on the clinical question (for example, diagnosing coronary disease vs. assessing the effect of treatment), the cardiologist may ask the patient to temporarily withhold some of these medications before the scan.
Intravenous aminophylline is used in the imaging suite to reverse severe or persistent side effects of adenosine, regadenoson, or dipyridamole. Aminophylline itself has interactions and contraindications that the medical team will consider if it needs to be used.
Interactions Relevant to Cardiac PET with Rubidium-82
| Drug / Substance | Type of Interaction | Clinical Effect | Recommendation |
|---|---|---|---|
| Caffeine (coffee, tea, cola, chocolate) | Pharmacodynamic (adenosine antagonist) | May blunt the response to vasodilator stress, reducing scan sensitivity | Avoid for at least 12–24 hours before the scan |
| Theophylline / aminophylline | Pharmacodynamic (adenosine antagonist) | Blocks vasodilator effect; used intravenously to reverse stress-agent side effects | Hold oral methylxanthines ≥24 h before stress PET per local protocol |
| Beta-blockers | Pharmacodynamic | Reduces heart rate response; may mask ischaemia | Withhold only if cardiologist requests, based on scan indication |
| Nitrates (e.g., isosorbide mononitrate) | Pharmacodynamic | May reduce severity of reversible ischaemia on imaging | Follow cardiologist’s instructions regarding temporary discontinuation |
| Calcium channel blockers | Pharmacodynamic | May attenuate stress-induced perfusion abnormalities | Individualised decision based on clinical question |
| Dipyridamole (oral) | Pharmacodynamic | Potentiates the effect of IV adenosine or regadenoson | Hold for ≥24 hours before the scan, if clinically acceptable |
| Other diagnostic radiopharmaceuticals | Imaging interference | Residual activity from recent nuclear medicine tests can affect PET images | Inform the team of any recent PET or SPECT scans |
The table above is a summary and is not a complete list of all possible interactions. Always tell the nuclear medicine staff and referring cardiologist about all medications you are taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements, before a cardiac PET study with RUBY-FILL. The team will advise which medications can continue as usual and which, if any, should be temporarily paused.
Most centres ask patients to fast for 4–6 hours before a rubidium-82 PET stress study and to avoid all caffeine-containing products for 12–24 hours. Small sips of water to take essential non-cardiac medications are usually allowed. Always follow the specific preparation instructions given by your imaging centre.
What Is the Correct Dose of RUBY-FILL?
The administered activity of rubidium-82 chloride eluted from RUBY-FILL is typically 1,110–2,220 MBq (30–60 mCi) per injection, usually given as a rapid intravenous bolus using a validated infusion system. Two injections are given per study – one at rest and one during pharmacologic stress – with the exact activity individualised based on scanner type, patient weight, and imaging protocol.
Dosing in nuclear medicine is expressed in units of radioactivity (becquerels, Bq, or curies, Ci), not in milligrams. This reflects the fact that the diagnostic signal depends on the number of radioactive decays, not on the chemical mass of the tracer. For rubidium-82 from RUBY-FILL, the administered activity is calibrated precisely by the infusion system at the moment of injection, based on the generator’s current elution yield.
Adults
Standard Adult Dosage
The recommended administered activity of rubidium-82 chloride for adult cardiac PET imaging is typically 1,110–2,220 MBq (30–60 millicuries) per injection, given as a rapid intravenous bolus over a few seconds. Most protocols use two administrations per study: one at rest and one during pharmacologic stress. The exact activity is determined by the nuclear medicine physician or physicist, taking into account the PET scanner model (2D vs. 3D acquisition, list mode capabilities), the patient’s body weight, and the imaging protocol (gated vs. non-gated, with or without dynamic quantification of myocardial blood flow).
Image acquisition begins almost immediately after injection, because rubidium-82 reaches the heart within seconds and its short half-life means most of the detectable activity is gone within a few minutes. Stress imaging is performed during the peak effect of the pharmacologic stress agent, typically 10–20 minutes after the rest acquisition.
Children and Adolescents
Paediatric Use
RUBY-FILL is not indicated for use in paediatric patients. The safety and efficacy of rubidium-82 PET myocardial perfusion imaging in children and adolescents under 18 years of age have not been established. Coronary artery disease is very uncommon in this age group, and any cardiac imaging in paediatric patients should be performed under the direction of a specialist paediatric cardiologist and nuclear medicine physician using age-appropriate alternatives whenever possible.
Elderly Patients
Geriatric Dose Considerations
No dose adjustment of rubidium-82 is generally required based on age alone. However, elderly patients may be more likely to have comorbidities (for example, severe coronary artery disease, AV block, sick sinus syndrome, or COPD) that influence the choice of pharmacologic stress agent. The medical team will review cardiovascular history and medications carefully before deciding on the stress protocol.
Missed Appointment
Unlike long-term medications, RUBY-FILL is not a drug that patients take at home on a schedule. If you miss your scheduled cardiac PET appointment, simply contact the imaging centre to rebook. You do not need to take any “missed dose” – the scan is performed on a specific date and time, and your medical team will advise you about any preparation (fasting, holding caffeine, holding certain medications) that should be repeated before the new appointment.
Overdose
Accidental over-administration of rubidium-82 from RUBY-FILL is very unlikely because the generator is used with a validated automated infusion system that measures the administered activity in real time and stops the injection when the prescribed activity has been delivered. In the rare event of over-administration, the main consequence would be a slightly higher radiation dose to the patient. Because of the very short half-life of rubidium-82, measures such as hydration and frequent voiding can help reduce the absorbed dose. Facilities follow specific quality-assurance protocols and will report any significant deviation from the intended activity to the appropriate regulatory authority.
| Patient Group | Typical Administered Activity | Notes |
|---|---|---|
| Adults, rest PET | 1,110–2,220 MBq (30–60 mCi) | Individualised to scanner type and body weight |
| Adults, stress PET | 1,110–2,220 MBq (30–60 mCi) | Given at peak effect of vasodilator or dobutamine stress |
| Elderly (≥65 years) | As per adult protocol | Careful screening for stress-agent contraindications |
| Children (<18 years) | Not established | RUBY-FILL is not indicated for paediatric use |
| Severe renal or hepatic impairment | As per adult protocol | Tracer clearance is dominated by physical decay; adjust co-medications |
| Pregnant patients | Generally avoided | Only if benefit clearly outweighs fetal radiation risk |
What Are the Side Effects of RUBY-FILL?
Side effects directly attributable to rubidium-82 from RUBY-FILL are rare because of its very short half-life and extremely small chemical mass. Most symptoms reported during cardiac PET are related to the pharmacologic stress agent used alongside the tracer. Serious adverse reactions are uncommon when appropriate patient selection and monitoring protocols are followed.
Adverse reactions to diagnostic radiopharmaceuticals are generally uncommon, and rubidium-82 chloride is no exception. Because the amount of chemical substance injected is extremely small – measured in picomoles – classical dose-dependent pharmacological side effects are essentially absent. The radiation dose delivered per scan is also low relative to many other cardiac imaging tests. Nevertheless, as with any radiopharmaceutical, rare idiosyncratic or allergic reactions have been reported in the scientific literature and in post-marketing surveillance.
In routine clinical practice, patients undergoing cardiac PET often do experience symptoms during the scan – but these are typically caused by the pharmacologic stress agent, not by RUBY-FILL itself. Regadenoson, adenosine, and dipyridamole act as potent coronary vasodilators and can cause transient flushing, shortness of breath, chest discomfort, headache, dizziness, and gastrointestinal symptoms. These symptoms generally resolve within a few minutes once the infusion is stopped, or more quickly with administration of intravenous aminophylline, which antagonises the stress agent.
Radiation itself does not cause acute, noticeable symptoms at the doses used for rubidium-82 PET. The radiation dose is quantified as an effective dose, typically 3–5 mSv for a full rest/stress study (without CT attenuation correction). This is comparable to the radiation exposure from a few months of natural background radiation and is substantially lower than the cumulative dose from several years of SPECT myocardial perfusion imaging with thallium-201. Long-term radiation risks from a single study are considered very small relative to the diagnostic benefit in appropriately selected patients.
All suspected adverse reactions to radiopharmaceuticals should be reported to the national pharmacovigilance authority (for example, the FDA MedWatch programme in the United States, the MHRA Yellow Card scheme in the United Kingdom, or the equivalent regulatory body in other countries). Reporting helps build the safety evidence base for rubidium-82 PET imaging.
Common Side Effects
May affect up to 1 in 10 patients (mostly caused by the pharmacologic stress agent)
- Transient chest discomfort or tightness
- Shortness of breath or feeling of breathlessness
- Flushing or warm sensation
- Headache
- Dizziness or lightheadedness
- Mild nausea or abdominal discomfort
Uncommon Side Effects
May affect up to 1 in 100 patients
- Palpitations or transient arrhythmia
- Transient atrioventricular (AV) block
- Drop or rise in blood pressure
- Fatigue after the scan
- Metallic or unusual taste in the mouth
- Local reaction at the intravenous injection site (mild pain, redness)
Rare Side Effects
May affect fewer than 1 in 1,000 patients
- Severe bronchospasm (especially with vasodilator stress agents in patients with asthma/COPD)
- Severe hypotension or syncope
- Prolonged or symptomatic AV block
- Serious hypersensitivity or anaphylactoid reaction to the tracer
- Myocardial infarction or significant arrhythmia during stress
- Seizure (reported very rarely, particularly with aminophylline reversal)
Severe or persistent chest pain; severe shortness of breath; swelling of the face, lips, tongue, or throat; severe dizziness or fainting; severe rash with blisters; or any new neurological symptoms such as weakness, difficulty speaking, or seizures. These symptoms are very rare after a rubidium-82 PET scan but require urgent evaluation. Call your local emergency number or go to the nearest emergency department.
The radiation exposure from a rubidium-82 PET study is considered low and is justified by the significant diagnostic value of the scan in patients with suspected coronary artery disease. However, any radiation exposure carries a small theoretical long-term risk, and cumulative radiation exposure over a lifetime is considered when ordering imaging tests, especially in younger patients. Your nuclear medicine physician will always weigh the expected benefit of the scan against the radiation dose.
How Is RUBY-FILL Stored and Handled?
RUBY-FILL generators are stored and used only in licensed nuclear medicine facilities. They are kept in dedicated shielded areas that comply with national radiation-safety regulations. Patients do not store RUBY-FILL at home – the product is supplied directly to hospitals and imaging centres and is discarded by trained personnel after its authorised use period.
RUBY-FILL is supplied as a pre-assembled, shielded strontium-82/rubidium-82 generator designed to be connected to a validated infusion system in a dedicated cardiac PET suite. Because the generator contains radioactive strontium-82 and produces radioactive rubidium-82 on demand, it is subject to strict national and international radiation-safety regulations. Handling is permitted only by appropriately licensed personnel in facilities authorised to work with radioactive materials.
Storage of the generator follows the manufacturer’s labelling and national regulatory requirements. The generator is typically stored at controlled room temperature within its protective shielding, in a secure area with restricted access. Environmental monitoring – including radiation surveys, contamination wipe tests, and quality-control elutions – is performed regularly to ensure safe and reliable operation. The infusion system is tested daily for parameters such as elution volume, tracer yield, and strontium breakthrough before any patient is injected.
The authorised use period of a RUBY-FILL generator is determined by the radioactive decay of its parent nuclide (strontium-82) and by the manufacturer’s quality specifications. After the generator has reached its expiry, it must be returned for safe disposal according to local regulations and the manufacturer’s take-back procedures. Generators and related materials are never disposed of in general waste, because they may contain residual radioactive material.
You will not be given any RUBY-FILL medication to take home, and you do not need to do anything to “store” the tracer. After your scan, the very small amount of rubidium-82 in your body decays rapidly (half-life ~75 seconds) and the remaining activity is excreted through the kidneys over the following hours. Most nuclear medicine departments will provide simple advice about hydration and voiding after the scan.
What Does RUBY-FILL Contain?
RUBY-FILL is a generator that contains strontium-82 adsorbed onto a shielded column. When eluted with sterile normal saline, it produces a sterile, pyrogen-free solution of rubidium-82 chloride (Rb-82 Cl) for intravenous injection.
The active radionuclide produced by RUBY-FILL is rubidium-82 (Rb-82), a positron-emitting radioisotope. Rubidium-82 is generated within the device by the decay of its parent nuclide, strontium-82 (Sr-82). Strontium-82 itself is produced in a cyclotron or particle accelerator and is then firmly adsorbed onto a hydrous tin(IV) oxide or similar chromatographic matrix inside the generator. Because strontium-82 remains bound to the column, only rubidium-82 is eluted when sterile saline is passed through the generator.
The chemical form of the administered tracer is rubidium chloride (RbCl) in isotonic sodium chloride solution. Rubidium behaves as a potassium analogue in the body and is actively taken up by myocardial cells through the Na/K-ATPase pump, which is why it is an excellent tracer of regional myocardial blood flow.
Excipients in the eluate consist primarily of sterile sodium chloride for injection (the eluting solvent). The solution is pyrogen-free and suitable for direct intravenous administration. The chemical mass of rubidium administered is extremely small (picomolar range), so the product cannot induce classical pharmacological or allergic reactions related to mass effect.
Every batch of RUBY-FILL generators is manufactured according to pharmaceutical good manufacturing practice (GMP) standards, and each elution is subject to quality-control checks before patient administration. Key release criteria include sterility, apyrogenicity, radiochemical purity, radionuclidic purity (strontium-82 and strontium-85 breakthrough limits), chemical purity, and pH. These measures ensure that the rubidium-82 chloride injected into patients meets the highest pharmaceutical and radiopharmaceutical quality standards.
Frequently Asked Questions About RUBY-FILL
A cardiac PET scan using rubidium-82 chloride produced by RUBY-FILL is used to assess myocardial perfusion – the blood flow to the muscle of the heart – at rest and during pharmacologic stress. It is most commonly performed in adults with known or suspected coronary artery disease, in patients with chest pain or unexplained shortness of breath, or to assess the consequences of previous heart attacks or revascularisation procedures (such as stents or coronary bypass surgery). The images help cardiologists decide whether further investigations or treatments are needed.
A typical rubidium-82 rest/stress cardiac PET study takes approximately 30–45 minutes from start to finish, depending on local protocols, scanner type, and whether additional imaging (such as CT for attenuation correction, calcium scoring, or coronary CT angiography) is performed at the same visit. The injection of rubidium-82 itself takes only seconds, and image acquisition for each phase (rest and stress) typically lasts around 5–7 minutes. The short half-life of rubidium-82 allows both rest and stress acquisitions to be completed within a single appointment.
The typical effective radiation dose from a rest/stress rubidium-82 cardiac PET study is approximately 3–5 mSv, although this can vary based on administered activity, scanner technology, and whether additional CT imaging is used. For comparison, natural background radiation exposure is around 2–3 mSv per year in many countries, and a conventional SPECT myocardial perfusion scan can deliver 6–12 mSv or more. The dose from a cardiac PET study is usually considered low to moderate in the context of its diagnostic value, but your nuclear medicine physician will always weigh the benefit against the radiation exposure before the scan.
Yes. Most centres ask you to:
- Avoid all caffeine-containing products (coffee, tea, cola, energy drinks, chocolate, some over-the-counter medicines) for at least 12–24 hours before the scan, because caffeine can block the vasodilator stress agent
- Fast for 4–6 hours before the scan, though small sips of water are usually allowed for taking essential medications
- Follow specific instructions about holding certain cardiac medications (for example, nitrates or theophylline), if advised by your cardiologist
- Wear loose, comfortable clothing and avoid metal objects above the waist that could interfere with imaging
Your imaging centre will give you tailored preparation instructions based on your specific scan protocol.
Rubidium-82 from RUBY-FILL does not require the same renal dose adjustments as some other contrast agents or medications, because the tracer is largely eliminated through radioactive decay within minutes of administration. The very short half-life and small chemical mass mean that rubidium-82 itself is unlikely to worsen kidney function. However, patients with severe kidney disease may have additional considerations – for example, regarding co-administered CT contrast if coronary CT angiography is combined with the PET, or regarding medications used alongside the scan. Always inform the medical team about your kidney function before the scan.
Because rubidium-82 has a physical half-life of only about 75 seconds, essentially all the radioactivity has decayed within minutes after the injection. For practical purposes, patients are not significantly radioactive by the time they leave the scanner. Unlike some longer-lived radiopharmaceuticals (for example, iodine-131 used in thyroid treatment), no specific precautions are usually required for contact with family members, pregnant women, or children after a rubidium-82 PET scan. If additional tracers or therapies are used during the same visit, the team will provide any necessary radiation-safety instructions.
In most cases, yes – rubidium-82 itself does not affect your ability to drive. However, some patients experience lingering effects from the pharmacologic stress agent (for example, fatigue, mild dizziness, or transient chest discomfort). Your nuclear medicine team will observe you for a short period after the scan and will advise whether it is safe to drive or whether you should arrange for someone to drive you home. If you received sedation or certain other medications as part of the examination, you should not drive until the effects have fully worn off.
References and Sources
This article is based on internationally recognised medical and pharmaceutical guidelines and peer-reviewed literature. All information has been reviewed by qualified healthcare professionals and follows evidence-based principles.
- U.S. Food and Drug Administration (FDA). RUBY-FILL (Rubidium Rb 82 Generator) – Prescribing Information. FDA, 2016 (updated). Available at: www.accessdata.fda.gov
- European Medicines Agency (EMA). Guideline on Radiopharmaceuticals. EMA/CHMP/QWP, 2023. Available at: www.ema.europa.eu
- World Health Organization (WHO). Basic Safety Standards for Protection against Ionizing Radiation and for the Safety of Radiation Sources. WHO/IAEA, 2023.
- Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC/SNMMI Imaging Guideline: PET Nuclear Cardiology Procedures. Journal of Nuclear Cardiology. 2016;23(5):1187–1226. doi:10.1007/s12350-016-0522-3
- Verberne HJ, Acampa W, Anagnostopoulos C, et al. EANM Procedural Guidelines for Radionuclide Myocardial Perfusion Imaging with SPECT and SPECT/CT: 2015 Revision. European Journal of Nuclear Medicine and Molecular Imaging. 2015;42:1929–1940. doi:10.1007/s00259-015-3139-x
- Henzlova MJ, Duvall WL, Einstein AJ, et al. ASNC Imaging Guidelines for SPECT Nuclear Cardiology Procedures: Stress, Protocols, and Tracers. Journal of Nuclear Cardiology. 2016;23(3):606–639.
- International Commission on Radiological Protection (ICRP). ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals. Annals of the ICRP. 2015;44(2S).
- Chow BJW, Beanlands RS (eds.). Cardiac PET and PET/CT Imaging. 2nd Edition. Springer, 2023.
- British National Formulary (BNF). Prescribing Guidance: Diagnostic Radiopharmaceuticals. NICE, 2024. Available at: bnf.nice.org.uk
- Murthy VL, Bateman TM, Beanlands RS, et al. Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC. Journal of Nuclear Medicine. 2018;59(2):273–293.
About the Medical Editorial Team
This article has been written and reviewed by iMedic’s Medical Editorial Team, consisting of licensed physicians and specialists in nuclear medicine, cardiology, and clinical pharmacology with expertise in radiopharmaceuticals, drug safety, and evidence-based medicine.
iMedic Medical Editorial Team – specialists in nuclear medicine, cardiac imaging, and clinical pharmacology. All content is researched and written using peer-reviewed sources and international guidelines from ASNC, SNMMI, EANM, and ICRP.
iMedic Medical Review Board – independent panel of qualified physicians who review all drug information content for accuracy, completeness, and clinical relevance according to EMA, FDA, WHO, and EANM standards.
Editorial Standards: All pharmaceutical and radiopharmaceutical content on iMedic follows strict editorial standards based on the GRADE evidence framework. We do not accept any form of pharmaceutical industry sponsorship or advertising. Our content is independent, evidence-based, and written for patients and caregivers. Read more about our editorial standards.